Regulus Therapeutics Inc. (NASDAQ:RGLS) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 3,529,089 shares, an increase of 32.7% from the August 15th total of 2,660,204 shares. Based on an average daily volume of 552,900 shares, the short-interest ratio is currently 6.4 days. Approximately 4.6% of the company’s stock are sold short.

A number of research firms have recently commented on RGLS. Chardan Capital cut Regulus Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 2nd. Needham & Company LLC reissued a “hold” rating on shares of Regulus Therapeutics in a research note on Wednesday, August 2nd. Wedbush reissued an “ourperform” rating and issued a $4.00 target price on shares of Regulus Therapeutics in a research note on Monday, August 7th. Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research note on Wednesday, July 12th. Finally, BMO Capital Markets set a $1.00 target price on Regulus Therapeutics and gave the stock a “hold” rating in a research note on Monday, June 12th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company. Regulus Therapeutics currently has an average rating of “Hold” and a consensus target price of $3.58.

Regulus Therapeutics (NASDAQ:RGLS) opened at 1.31 on Friday. The company’s market capitalization is $135.96 million. Regulus Therapeutics has a one year low of $0.79 and a one year high of $3.65. The stock’s 50 day moving average price is $0.99 and its 200-day moving average price is $1.23.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). Regulus Therapeutics had a negative return on equity of 173.20% and a negative net margin of 31,460.47%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. Equities analysts forecast that Regulus Therapeutics will post ($1.02) EPS for the current year.

In related news, Director William H. Rastetter bought 274,725 shares of the business’s stock in a transaction dated Tuesday, July 25th. The shares were purchased at an average cost of $0.91 per share, with a total value of $249,999.75. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Daniel R. Chevallard bought 54,945 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was bought at an average cost of $0.91 per share, for a total transaction of $49,999.95. Following the completion of the purchase, the chief financial officer now owns 59,415 shares of the company’s stock, valued at approximately $54,067.65. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 549,450 shares of company stock worth $500,000. 4.80% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in RGLS. Teachers Advisors LLC grew its stake in Regulus Therapeutics by 15.7% during the 4th quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 9,804 shares during the last quarter. Wells Fargo & Company MN grew its stake in Regulus Therapeutics by 13.5% during the 1st quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 93,295 shares during the last quarter. South Dakota Investment Council grew its stake in Regulus Therapeutics by 16.3% during the 1st quarter. South Dakota Investment Council now owns 1,327,058 shares of the biopharmaceutical company’s stock worth $2,190,000 after buying an additional 186,130 shares during the last quarter. Tudor Investment Corp ET AL grew its stake in Regulus Therapeutics by 131.5% during the 1st quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 61,373 shares during the last quarter. Finally, Wedbush Securities Inc. grew its stake in Regulus Therapeutics by 10.3% during the 2nd quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock worth $197,000 after buying an additional 18,600 shares during the last quarter. Hedge funds and other institutional investors own 21.93% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/09/16/regulus-therapeutics-inc-rgls-sees-significant-increase-in-short-interest.html.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.